Anamar Ab Is Developing A First In Classanti Fibrotic Medicineto Preventslow And Heal Scarring Caused By Fibrosis Through Its Patented Suiteof Serotonin5 Ht2Breceptor Antagonistsour Selectiveoral 5 Ht2B Receptor Antagonistam1476Has Broad Therapeutic Potential Across Fibrotic Conditionswhich Affect Millions Of Patients But Havelimitedif Anytreatment Optionsincluding Systemic Fibrotic Disorders And Organ Specific Fibrotic Disorders Such As Interstitial Lung Diseasesam1476 Performed Successfully In In Vitro And In Vivo Models Of Fibrosisas Well As Demonstrating Favourablesafety And Pharmacokinetic Profiles In Phasei Clinical Studiesit Offers A Uniquedual Action Approach To Treat Skin And Lung Manifestations Of Systemic Sclerosis By Targeting Peripheral 5 Ht2B Receptors Our Antagonists Will Halt Key Signaling Pathways Associated With Fibrosisthis Specifically Reduces 5 Ht Induced Myofibroblast And Macrophageactivity And Tgf I Productionminimizing Sideeffects And Interactions With Other Medicineswearecombining Our Innovativetherapeutic Platform With Biomarkers And Genetic Analysis To Identify Thosepatients Most Likely To Benefit From Treatmentusing Our Heritagein Diagnostics To Ensuring Thebest Outcomes For Thosewith Fibrosis
No conferences found for this company.
| Company Name | Anamar Ab |
| Country |
Sweden
|
| Address | Medicon Village Scheeletorget 1 Se 223 81 Lund Sweden |
| Telephone | Login to View |
| Login to View |
